{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:28:34Z","timestamp":1794472114010,"version":"4.9.1"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0461-4","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T04:49:50Z","timestamp":1543985390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor\u2013induced colitis: a multi-center study"],"prefix":"10.1136","volume":"6","author":[{"given":"Hamzah","family":"Abu-Sbeih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Charabaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"461_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"461_CR2","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6140\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"461_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"461_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270\u20131.","journal-title":"N Engl J Med"},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"461_CR6","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab with Tumor Response and Survival among Patients with Advanced Melanoma. Jama. 2016;315:1600\u20139.","journal-title":"Jama"},{"key":"461_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"461_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37.","journal-title":"J Immunother Cancer"},{"key":"461_CR9","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","journal-title":"J Clin Oncol"},{"key":"461_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.","journal-title":"J Immunother Cancer"},{"key":"461_CR11","doi-asserted-by":"publisher","first-page":"iv119-iv42","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv42.","journal-title":"Ann Oncol"},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.","journal-title":"J Immunother Cancer"},{"key":"461_CR13","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018:Jco2017776385.","DOI":"10.1200\/JOP.18.00005"},{"key":"461_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","volume":"6","author":"DH Johnson","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103.","journal-title":"J Immunother Cancer"},{"key":"461_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785\u201392.","journal-title":"J Clin Oncol"},{"key":"461_CR16","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ (Clinical research ed). 2017;357:j1415.","journal-title":"BMJ (Clinical research ed)"},{"key":"461_CR17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/ard.2008.100008","volume":"68","author":"JN Hoes","year":"2009","unstructured":"Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833\u20138.","journal-title":"Ann Rheum Dis"},{"key":"461_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"461_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"key":"461_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2796.2012.02588.x","volume":"272","author":"J Marsal","year":"2012","unstructured":"Marsal J, Agace WW. Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012;272:411\u201329.","journal-title":"J Intern Med"},{"key":"461_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","volume":"74","author":"C Berlin","year":"1993","unstructured":"Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185\u201395.","journal-title":"Cell"},{"key":"461_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. \n                    https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf\n                    \n                   2018."},{"key":"461_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/ecco-jcc\/jjv111","volume":"9","author":"T Lobaton","year":"2015","unstructured":"Lobaton T, Bessissow T, De Hertogh G, et al. The modified Mayo endoscopic score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients. Journal of Crohn's & colitis. 2015;9:846\u201352.","journal-title":"Journal of Crohn's & colitis"},{"key":"461_CR24","doi-asserted-by":"crossref","unstructured":"Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ case reports. 2016;2016.","DOI":"10.1136\/bcr-2016-216641"},{"key":"461_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer immunology, immunotherapy : CII. 2017;66:581\u201392.","journal-title":"Cancer immunology, immunotherapy : CII"},{"key":"461_CR26","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681\u20138.","journal-title":"Clin Cancer Res"},{"key":"461_CR27","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19:3977\u201386.","journal-title":"Clin Cancer Res"},{"key":"461_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0000000000000165","volume":"25","author":"KM Felice De","year":"2015","unstructured":"De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25:321\u20137.","journal-title":"Melanoma Res"},{"key":"461_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66:839\u201351.","journal-title":"Gut"},{"key":"461_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14:348\u201354.e17.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"461_CR31","doi-asserted-by":"crossref","unstructured":"Choi K, Abu-Sbeih H, Samdani R, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflammatory bowel diseases 2018.","DOI":"10.1093\/ibd\/izy240"},{"key":"461_CR32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24:1695\u2013705.","journal-title":"Inflamm Bowel Dis"},{"key":"461_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","volume":"14","author":"EC Verschuren","year":"2016","unstructured":"Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of Ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836\u201342.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"461_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/ecco-jcc\/jjv131","volume":"9","author":"DN Rasmussen","year":"2015","unstructured":"Rasmussen DN, Karstensen JG, Riis LB, Brynskov J, Vilmann P. Confocal laser Endomicroscopy in inflammatory bowel disease--a systematic review. Journal of Crohn\u2019s & colitis. 2015;9:1152\u20139.","journal-title":"Journal of Crohn\u2019s & colitis"},{"key":"461_CR35","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.","journal-title":"Nat Commun"},{"key":"461_CR36","doi-asserted-by":"publisher","unstructured":"Wang Y, Wiesnoski D. Helmink B, et al. Nature Medicine: Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis; 2018. \n                    https:\/\/doi.org\/10.1038\/s41591-018-0238-9\n                    \n                  .","DOI":"10.1038\/s41591-018-0238-9"},{"key":"461_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3892\/br.2016.751","volume":"5","author":"M Chatzikonstantinou","year":"2016","unstructured":"Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, et al. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomedical reports. 2016;5:403\u20137.","journal-title":"Biomedical reports"},{"key":"461_CR38","doi-asserted-by":"publisher","first-page":"2483261","DOI":"10.1155\/2016\/2483261","volume":"2016","author":"E Abej","year":"2016","unstructured":"Abej E, El-Matary W, Singh H, Bernstein CN. The utility of fecal calprotectin in the real-world clinical Care of Patients with inflammatory bowel disease. Canadian journal of gastroenterology & hepatology. 2016;2016:2483261.","journal-title":"Canadian journal of gastroenterology & hepatology"},{"key":"461_CR39","first-page":"11","volume":"10","author":"D Berman","year":"2010","unstructured":"Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.","journal-title":"Cancer Immun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0461-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0461-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0461-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:43:15Z","timestamp":1601041395000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0461-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0461-4","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"3 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Boards at The University of Texas MD Anderson Cancer Center and Medstar-Georgetown University Center granted a waiver of informed consent for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"142"}}